A Mounjaro dose increase is planned, not a sign anything is wrong: GLP-1 treatment starts low and rises in steps so your digestive system has time to adjust, which keeps side effects milder. The starting dose is a stepping stone rather than the destination, and the schedule of increases, known as titration, is set by your prescriber and built into how these medicines are licensed.
Is Mounjaro a GLP-1, and what is a GLP-1?
GLP-1 stands for glucagon-like peptide-1, a natural gut hormone released after eating that helps control appetite and blood sugar. Medicines in this class mimic that hormone to reduce hunger and slow how quickly the stomach empties. Wegovy (semaglutide) is a GLP-1 receptor agonist. Mounjaro (tirzepatide) acts on the GLP-1 receptor and a second receptor called GIP, so it is often grouped with the GLP-1 medicines while working on two pathways rather than one. We explain the mechanism in more detail in how Mounjaro works. Whichever medicine you are on, the dose is built up gradually rather than started at full strength.
What titration means
Titration simply means adjusting a dose in steps to reach the right level for a person. With GLP-1 treatment, you begin on a low dose and move up on a set schedule, staying at each level for a period before the next increase. It is a standard approach for many medicines where the body needs time to adapt, and it is written into the product licence rather than being optional guidance. The clinical trials that led to these medicines being approved used stepped dosing, so the schedule you follow reflects how the treatment was actually studied and shown to work.
Why not start at the full dose?
Because the most common side effects, mostly gastrointestinal ones such as nausea, are strongly linked to how quickly the dose rises. Jumping straight to a higher dose tends to cause more of these effects without improving long-term results. A gentle build-up lets the body adapt, so most people tolerate treatment better. This is exactly why the Mounjaro Summary of Product Characteristics and the Wegovy Summary of Product Characteristics both specify a stepped escalation rather than a single starting strength. If you want the detail on the effects themselves, see GLP-1 treatment side effects.
What are the doses of Mounjaro and Wegovy?
The exact steps and timings depend on the medicine and on you, and your prescriber may hold or adjust them. As a general outline of the licensed schedules:
- Mounjaro (tirzepatide) usually starts at 2.5 mg once weekly for four weeks, then increases to 5 mg. Further increases of 2.5 mg can follow after at least four weeks at a dose, with maintenance typically at 5 mg, 10 mg or 15 mg once weekly. See Mounjaro for more.
- Wegovy (semaglutide) usually starts at 0.25 mg once weekly, then steps up roughly every four weeks through 0.5 mg, 1 mg and 1.7 mg to a maintenance dose of 2.4 mg once weekly. See Wegovy for more.
You stay on each dose long enough for your body to settle before moving up, and increases only happen when it is appropriate. Your prescriber sets this out and checks in along the way, so the schedule you follow may differ from the outline above.
When to pause the climb
The schedule is a guide, not a race. If side effects are troublesome at a given step, your prescriber may hold you at that dose for longer, or adjust the plan. Staying a little longer at one level is common and sensible; it is better than pushing up and struggling. Simple measures such as smaller meals and steady hydration also help, and our guide to managing nausea on GLP-1s covers these in detail. A Mounjaro dose increase should never feel like something to endure quietly.
What to expect in the first weeks
On the lowest dose, many people notice a modest reduction in appetite and only limited weight change, which is expected. The dose is doing its job of letting your body adjust, not delivering its full effect. Nausea, if it appears, is usually mildest in the days just after an increase and tends to ease as your body settles at that level. Most of the appetite reduction and weight loss tends to come as you reach the higher maintenance doses, which is why patience through the early steps matters. It also explains why comparing your early results with someone further along their schedule is rarely useful. Our guide to the first 12 weeks of GLP-1 treatment walks through this timeline week by week.
Why this matters for results
Sticking with treatment is what drives results over time, and people are far more likely to stick with something they tolerate. A gradual, well-managed build-up is not caution for its own sake; it is how treatment is made sustainable. Pushing the dose up faster than the schedule allows tends to trade a little short-term impatience for a lot of avoidable discomfort, without getting you to your goal any sooner. It can also mean stopping treatment early because the side effects became too much, which is the opposite of what a faster climb was meant to achieve. Following the planned Mounjaro dose increase, and pausing when your body needs it, is the approach most likely to keep you on treatment long enough to benefit. If in doubt about any change, your prescriber is the person to ask rather than adjusting the dose yourself.
